http://orcid.org/0000-0002-8636-8097
Figures
Abstract
Liver cancer is an emerging global health issue, with rising incidence in both the United States and the economically developing world. Although Guatemala experiences the highest rates of this disease in the Western hemisphere and a unique 1:1 distribution in men and women, few studies have focused on this population. Thus, we determined the prevalence and correlates of aflatoxin B1 (AFB1) exposure and hepatitis virus infection in Guatemalan adults. Healthy men and women aged ≥40 years (n = 461), residing in five departments of Guatemala, were enrolled in a cross-sectional study from May—October of 2016. Serum AFB1-albumin adducts were quantified using isotope dilution mass spectrometry. Multivariate linear regression was used to assess relationships between AFB1-albumin adduct levels and demographic factors. Biomarkers of hepatitis B virus and hepatitis C virus infection were assessed by immunoassay and analyzed by Fisher’s exact test. AFB1-albumin adducts were detected in 100% of participants, with a median of 8.4 pg/mg albumin (range, 0.2–814.8). Exposure was significantly higher (p<0.05) in male, rural, low-income, and less-educated participants than in female, urban, and higher socioeconomic status participants. Hepatitis B and C seropositivity was low (0.9% and 0.5%, respectively). Substantial AFB1 exposure exists in Guatemalan adults, concurrent with low prevalence of hepatitis virus seropositivity. Quantitatively, AFB1 exposures are similar to those previously found to increase risk for liver cancer in Asia and Africa. Mitigation of AFB1 exposure may reduce liver cancer incidence and mortality in Guatemala, warranting further investigation.
Citation: Smith JW, Kroker-Lobos MF, Lazo M, Rivera-Andrade A, Egner PA, Wedemeyer H, et al. (2017) Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. PLoS ONE 12(12): e0189255. https://doi.org/10.1371/journal.pone.0189255
Editor: Isabelle Chemin, Centre de Recherche en Cancerologie de Lyon, FRANCE
Received: August 7, 2017; Accepted: November 22, 2017; Published: December 13, 2017
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Data Availability: All relevant data are within the paper.
Funding: This work was supported by National Institutes of Health grants P30CA006973-52S3 (JDG) and T32ES007141 (departmental award, supported JWS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
The increasing burden of cancer morbidity and mortality across diverse populations has emerged as a major global health concern for this century [1]. Primary liver cancer (LC) is emblematic of these global challenges. It is a common cancer, with nearly 800,000 cases and over 750,000 deaths worldwide in 2012 –fifth and second, respectively, among all cancer sites [2]. The burden of this highly lethal disease is not borne evenly, as LC occurs with a disproportionately high incidence in the economically developing world, where over 80% of new cases occur [3,4]. Although LC incidence and mortality still remain the highest in historically afflicted regions (China, southeastern Asia, sub-Saharan Africa) [5], global trends have begun to shift towards traditionally lower-risk countries. For example, while rates in China, the Philippines, and Singapore all decreased from 1993–2007, incidence in the United States, the United Kingdom, Canada, Australia, Germany, and Switzerland has risen [6]. In the United States, although death from most cancer types has been in decline, LC mortality increased between 2003–2012 at the highest rate of any organ site [7]. Such changes likely reflect shifts in factors that influence LC risk. LC is one of the few tumor types for which major etiological risk factors have been identified, which include chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), excessive alcohol consumption, obesity, nonalcoholic fatty liver disease and exposure to the foodborne mycotoxin, aflatoxin [2,8]. In China and Taiwan, vaccination against HBV coupled with reduced exposure to aflatoxin led to the declines in LC incidence seen in those populations [9–11], while obesity has likely contributed to the rise in LC in the U.S. [12].
Although LC etiology in Asian and African regions has been under constant investigation for decades and countries such as the U.S. have experienced rapid investments in research to combat increasing LC incidence, others have been left adrift amidst a rising epidemic. Guatemala, with an estimated age-standardized incidence of 16.0 per 100,000, is one such country. In fact, Guatemala suffers from the highest liver cancer incidence rate in the Western hemisphere, nearly three times that of the U.S. [4,5]. Put in context, this is a higher age-standardized rate than Japan, the Philippines, or Singapore, and only 30% lower than China. To our knowledge, no studies have investigated etiological factors contributing to the high rates of LC in Guatemala. Moreover, the distribution of LC within the Guatemalan population is unique–while in the vast majority of countries men have two- to three-fold higher rates of both LC incidence and death than women [6], in contrast, ratios in Guatemala are 1:1 [5]. Other countries in the region, such as El Salvador and Nicaragua, have similarly uncommon distributions, although lower rates of LC. The conventional disparity in LC incidence between sexes is commonly suggested to be the result of higher prevalence of LC risk factors in men than in women, but could be multifactorial and is not completely understood. Needless to say, given the dearth of work on LC in Guatemala, the factors driving the unusual distribution of LC incidence within this country is unclear. The high burden of LC, combined with its uncommon sex distribution, reveals a pressing need for the examination of risk factors driving this disease in Guatemala and Central America.
Aflatoxins are produced by molds of the genus Aspergillus–namely A. parasiticus and A. flavus [13,14]–and exposure occurs through consumption of contaminated commodity grains, particularly maize [13,14]. Aflatoxin B1 (AFB1) is the most toxic of the aflatoxins, and, since 1993, has been designated a known human carcinogen by the International Agency for Research on Cancer (IARC) [15,16]. Due to the widespread distribution of Aspergillus, uncontrolled food contamination in developing countries, and the carcinogenic potency of aflatoxins, exposure to AFB1 may account for one quarter of global liver cancer burden [17,18]. Maize is consumed as a staple crop throughout Latin America, making aflatoxin-contaminated food a potentially insidious health hazard in these countries. Aflatoxin contamination in Guatemala has been assessed in a small number of food survey analyses [19,20], including a recent survey of maize that found AFB1 contamination in 21 of the 22 departments of Guatemala [21]. While they demonstrate widespread contamination by aflatoxins, these surveys are compromised by the high heterogeneity of aflatoxin levels within a bulk of contaminated food [14] and, more fundamentally, cannot be used to predict subject-level dose. In contrast, biomarkers of aflatoxin exposure have been validated as measures of internal and biologically effective dose [13], and their epidemiological use has proven crucial to the establishment of aflatoxins as etiological agents of primary liver cancer [13,15,16,22,23]. In particular, the AFB1-serum albumin adduct [24,25] is useful not only for estimation of liver cancer risk [26], but also–thanks to the long half-life of albumin in circulation [27]–for monitoring past exposures on a timescale of months.
No studies to date have utilized validated biomarkers to assess aflatoxin exposure in Guatemalans—searches of PubMed, EMBASE, Scopus, and Web of Science for (“aflatoxin” AND “Guatemala”) returned zero relevant articles published on or before June 23, 2017. Furthermore, since hepatitis viruses are major etiological factors for LC [12,28] and HBV infection interacts with aflatoxin exposure to greatly increase liver cancer risk [22,23], hepatitis virus exposures should be assessed in conjunction with aflatoxin. Thus, the goal of this cross-sectional study was to assess the prevalence of aflatoxin, HBV and HCV exposure in Guatemalan adults, in order to better understand factors potentially driving this country’s high incidence of LC.
Methods
Subjects and study design
All participants provided written informed consent. All study procedures were approved by Institutional Review Boards at Johns Hopkins Bloomberg School of Public Health and the Institute of Nutrition of Central America and Panama (INCAP). Guatemalan men and women ≥ 40 years of age were recruited from cities in five Guatemalan departments: Chichicastenango (Quiché department), Escuintla (Escuintla), Mixco (Guatemala), San Lucas Tolimán (Sololá), and San Pablo Jocopilas (Suchitépequez). These cities were selected to represent urban (Escuintla, Mixco) and rural settings (Chichicastenango, San Lucas Tolimán, and San Pablo Jocopilas) throughout the country. Participants were recruited and enrolled between May and October of 2016. Maps of each community, when available, were used to pre-select households. Households were visited and a maximum of two non-blood-related participants per household were invited to participate in the study. We excluded pregnant women and individuals who could not provide informed consent. All field procedures were conducted by experienced, trained personnel. Demographic information was obtained during the initial home visit by study personnel-administered questionnaire. Ethnic background (indigenous or non-indigenous) was determined by participants’ self-identification. Serum samples were collected during a subsequent clinic visit; most samples were collected less than a week after the initial home visit. We enrolled a median of 93 participants from each locality (range, 84–101). In total, we contacted 677 households with 827 eligible individuals and enrolled 461 participants (56% response rate) from 358 households; 444 provided serum samples (Fig 1).
Numbers of households or participants at each stage of recruitment, for each department and for the final sample.
Aflatoxin B1 albumin adduct measurement and hepatitis B and C viral assessment
AFB1 exposure was assessed with minor variations to the method reported by McCoy et al. [29]. 443 of 444 serum samples collected had suitable volume for AFB1 analysis. Serum (250 μL) was spiked with an internal standard (0.5 ng AFB1-d4-lysine in 100 μL), combined with Pronase (EMD Millipore, Billerica MA, USA) protease solution (3.25 mg in 0.5 mL phosphate-buffered saline), and incubated for 18 h at 37°C. Solid-phase extraction–processed samples (Oasis MAX columns; Waters, Milford, MA, USA) were analyzed with isotope dilution mass spectrometry on a ThermoFisher Scientific TSQ Vantage (Waltham, MA, USA) in positive electrospray ionization mode. Peaks were manually integrated and AFB1-albumin lysine adducts (AFB1-lys) were normalized to total serum albumin as pg AFB1-lys/mg albumin. Serum total albumin was measured spectrophotometrically by ELISA, with minor modifications to manufacturer’s instructions (ab179887; Abcam, Cambridge, MA). The limit of quantification for this method was 0.2 pg AFB1-lys/mg albumin.
HBV infection status was assessed via determination of hepatitis B surface antigen (HBsAg) and total antibodies to hepatitis B core antigen (anti-HBc), while HCV status was assessed via testing for antibodies to hepatitis C virus (anti-HCV). All viral markers were assessed in the hepatitis diagnostic laboratory of Hannover Medical School as previously described [30].
Statistical analyses
Stata version 14 (StataCorp, College Station, TX, USA) and SAS v9.4 (Cary, NC, USA) were used for statistical analyses. The distribution of AFB1-lys was right-skewed and values were log10-transformed before analysis. We used multivariate linear regression to test for differences in AFB1-lys geometric means between demographic sub-groups, as well as to calculate marginally adjusted AFB1-lys geometric means with adjustment for age (continuous), sex, residence (urban vs. rural), and ethnicity (indigenous vs. non-indigenous). Sub-group differences in viral marker positivity were determined by Fisher’s exact test. Results were considered significant at p < 0.05.
Results
The sociodemographic characteristics of the study participants are depicted in Table 1. The mean age of the participants was 55.4 years overall– 58.0 years for men and 53.5 years for women. More women (n = 262, 58.6%) than men (n = 199, 43.2%) were recruited to the study. Over 60% of the participants came from rural communities and slightly more than half of participants (54.0%) self-identified as being of indigenous ancestry. In total, two-thirds of the study participants had 0–5 years of formal education and a similar fraction of the participants had a monthly income of 1,501–4,500 quetzales, which is approximately $200–600 USD.
Detectable levels of AFB1-lys were present in 100% of participants, with an overall range of 0.2–814.8 pg AFB1-lys/mg albumin and a median of 8.4 pg/mg. As seen in Fig 2 and Table 2, stratification by demographic factors revealed several statistically significant differences among these sub-groups. Men had significantly higher circulating levels of AFB1-lys adducts than women. Adduct levels in rural participants were more than two-fold higher than in their urban counterparts, as were levels in participants who self-identified as being of indigenous ethnicity compared to those who self-identified as non-indigenous. We also observed significantly lower AFB1-lys levels in participants with ≥ 6 years of education compared to 0–5 years, and aflatoxin biomarker levels decreased significantly with increasing monthly income. AFB1 exposure was not associated with age (Table 2). Interestingly, we observed an interaction in unadjusted geometric means between residence location and self-identified ethnic status. While AFB1 levels were lower among non-indigenous participants in urban vs. rural areas (rural: 11.9 pg/mg; 95% CI 8.8, 15.9; urban: 4.9 pg/mg; 4.2, 5.8), the same was not true for indigenous participants (rural: 13.4 pg/mg; 11.2, 16.0; urban: 17.4 pg/mg; 8.3, 36.8).
Unadjusted serum AFB1-albumin adducts overall and with stratification by sex, residence location, or ethnicity. All data are plotted on a base-10 logarithmic scale; dotted scale lines are drawn at 0.05, 0.5, 5, 50, and 500 pg/mg. Whiskers on boxplots extend to the 5th and 95th percentiles, with individual observations beyond those cutoffs plotted. *, p = 0.009 vs. male; †, p ≤ 0.0001 vs. rural; §, p ≤ 0.0001 vs. indigenous by multiple linear regression of unadjusted adduct values. Sample size n is displayed below each group. Non-I., non-indigenous; Indig., indigenous.
Differences by residence location and ethnicity were even more pronounced when further stratified by sex, as rural and indigenous men experienced some of the highest exposures of any sub-group within our analyses. Levels in rural men (15.5 pg/mg; 95% CI: 11.9, 20.2) were more than two-fold greater than urban male residents (6.1 pg/mg; 95% CI: 4.7, 7.9), while men who identified themselves as indigenous were similarly exposed to rural men (17.2 pg/mg; 95% CI: 13.0, 22.7) and had AFB1 exposures more than two times higher than their non-indigenous male counterparts (6.4 pg/mg, 95% CI: 5.0, 8.1). Indigenous, rural males had the highest AFB1-lys albumin geometric mean adduct levels (16.7 pg/mg; 95% CI: 12.5, 22.2).
Table 3 depicts AFB1-lys geometric means for each demographic subgroup, after simultaneous adjustment for all included demographic characteristics (age, sex, residence location, ethnicity, educational attainment, and income). After adjustment, only sex, residence location, education, and income remained significant predictors (p < 0.05) of AFB1-lys level.
The rates of HBV and HCV infection in this sample were low. Positivity for HBsAg was found in only 4 of 439 participants (0.9%), while only 2 of 441 tested positive for anti-HCV (0.5%). Due to low prevalence, statistical analysis was not carried out for HBsAg or anti-HCV markers. Sixty-one of 441 participants (13.8%) tested positive for anti-HBc. The prevalence of anti-HBc positivity was associated with residence location (8.2% urban, 17.3% rural; p = 0.007) and with indigenous ethnicity status (17.2% yes, 10.0% no; p = 0.037). Males trended towards a higher proportion of anti-HBc positivity than females (17.6% vs. 11.0%, respectively; p = 0.051). Only 0.5% of individuals (2 / 439) tested positive simultaneously for HBsAg and anti-HBc.
Discussion
In this study, we report the first examination of aflatoxin exposure in Guatemala using subject-level molecular biomarkers, alongside data showing low rates of HBV and HCV infection. Given the consumption of maize as a dietary staple throughout Central and South America, the affinity of Aspergillus species for colonization of maize, and the uncontrolled contamination of crops in much of the economically developing world [14], ingestion of aflatoxin-tainted food poses a threat of great damage to human health. While aflatoxin exposures in Mexico [31,32] and South America [33–36] have been documented with the use of subject-level biomarkers, no previous studies had examined exposures in Central American countries. Furthermore, given the fact that several nations in this region (Guatemala, El Salvador, Nicaragua) experience a highly unusual 1:1 ratio of LC incidence between men and women, studying these populations may reveal particular etiological insight. Finally, as LC in the United States is projected to rise most rapidly in the Hispanic community [37], knowledge of risk factors and disease patterns in Central America could be informative for a broader geographic region.
LC incidence is rising in the U.S., particularly among Hispanics [38,39]. While in part a result of HCV infection in the aging “baby-boomer” generation [6,12,40], LC is now largely driven by the growing contribution of metabolic disorders [12]. In particular, in a recent analysis, the constellation of obesity, non-alcoholic fatty liver disease, insulin resistance, diabetes, and metabolic syndrome accounted for nearly 40% of hepatocellular carcinoma incidence in U.S. Hispanics [12]. Not only were these metabolic disorders found to be the largest factors driving hepatocellular carcinoma incidence across all ethnicities, Hispanics experienced the highest population attributable fraction calculated for any of the ethnic groups examined [12]. Similarly, the metabolic perturbations of obesity and diabetes likely play a significant role in Guatemalan LC incidence. In the same sample as the current study, 30% of Guatemalan adults were found to be obese, 22% had diabetes, and 63% met criteria for metabolic syndrome [41]. Notably, these factors were more prevalent in women than in men, some by nearly three-fold (e.g., obesity, 41% vs. 15%, respectively). Although not tied to cancer incidence, this data suggests that obesity and its sequelae likely plays a significant role in Guatemalan LC burden and may contribute to its uncommon distribution between men and women.
Previous work has shown that any detectable aflatoxin exposure was associated with significantly increased risk of hepatocellular carcinoma [22,23]. Thus, the high prevalence of detectable AFB1 exposure in the current study (100%) suggests that aflatoxins may play a significant role in LC etiology in Guatemala. Moreover, since AFB1-lys dose reflects the formation of mutagenic AFB1-DNA adducts in vivo [42], greater magnitude of aflatoxin exposure leads to higher risk of liver carcinogenesis. Participants overall–and particularly those who were male, indigenous, and/or rural–had AFB1-lys adduct levels similar to regions in China which experienced endemic rates of LC into the 1980s, prior to the reductions in mortality attributable to decreased aflatoxin exposure [11]. Furthermore, the data reported in this study can be used to infer subject-level estimates of average daily AFB1 intake by interpolation of our AFB1-lys biomarker data with prior dose-response results from 14C-AFB1 micro-dosing [43,44], approximation of chronic exposure using AFB1-albumin adduct clearance kinetics [45], and correction for body weight. Estimates of average chronic AFB1 intake in this work ranged from 0.05–1,877 μg AFB1/day, with a median of 18.4 μg/d (quartile 1, 6.1 μg AFB1/day; quartile 3, 50.3 μg AFB1/day). These intake estimates are similar to quantitative food-based measurements of total daily AFB11 intake in other regions with high rates of liver cancer [46,47].
Among the sub-groups in our analysis, rural and indigenous Guatemalans experienced the highest levels of aflatoxin exposure. Moreover, males in each of these demographic sub-groups experienced further elevated AFB1 exposures. Previous studies in other populations have found that AFB1 exposure was associated with male sex in Taiwanese adults [48], residence location in children in Benin and Togo [49] and Tanzania [50], and ethnicity in pregnant Bangladeshis [51]. Additionally, we found an interaction in AFB1-lys levels between two of these factors, where unadjusted circulating adducts were lower in non-indigenous urban vs. non-indigenous rural participants, but equal in indigenous participants, regardless of location of residence. This interaction suggests that cultural or other factors affect aflatoxin adduct levels, perhaps through food choice or post-harvest practices [14]. However, ethnic self-identification and location of residence were closely related in our sample–the majority of rural participants self-identified as being of indigenous ancestry (83.0%), while urban participants were predominantly non-indigenous (91.6%). After simultaneous adjustment for all demographic characteristics, residence location, but not self-identified indigenous status, was significantly associated with AFB1 exposure. Further work will be required to fully dissect the impacts of these factors on aflatoxin exposure in Guatemala.
In addition to aflatoxin exposure, we assessed the prevalence of infection by HBV and HCV, which, when chronic, are major etiological factors of primary liver cancer [8,28]. Chronic HBV infection is defined as persistent HBsAg seropositivity for at least 6 months, which typically occurs alongside a positive anti-HBc result [52]. Seropositivity for anti-HCV suggests chronic infection with HCV [53]. Seminal work has previously demonstrated a greater-than-multiplicative interaction between concurrent aflatoxin exposure and chronic HBV infection, with estimates of liver cancer risk being 60-fold greater than with neither exposure [22,23]. The apparent low rates of chronic HBV and HCV infection observed in our study are similar to a previous country-level report from Guatemala [54], lower than regional estimates in Latin America [55], and much lower than historically endemic rates in Asia [56]. A vaccine for HCV is not available and improved HBV vaccination coverage in Guatemala is still needed—WHO has estimated that, in 2015, only 32% of newborns in the country were vaccinated by 1 year of age [57]. Despite this, rates of chronic HBV and HCV infection in Guatemala appear to be low, even while the country suffers from high rates of hepatocellular carcinoma. These data stand in contrast to aflatoxin exposure in Guatemala, which we report to be widespread and of significant magnitude.
Strengths of the current study include the sampling of diverse communities and, in particular, the use of subject-level molecular biomarkers to precisely determine aflatoxin exposure and HBV and HCV infection. Limitations of our study are the cross-sectional design and that the sampling method was not designed to be nationally representative. However, our sample demographics are similar to national-level estimates. In conclusion, this is the first study to measure biomarkers of aflatoxin exposure in Guatemala, a country which suffers from LC rates triple that of the Americas region as a whole. We have identified a high prevalence of exposure to AFB1, with quantitative levels similar to those previously found to increase risk for LC. Simultaneously, low rates of HBV and HCV infection suggest that these viruses may not play a major etiological role in LC in Guatemala. Combined with the high prevalence of obesity and metabolic syndrome, Guatemala presents a unique profile of LC risk factors (aflatoxin exposure, low HBV and HCV, high rates of obesity and fatty liver disease) that are similar to Hispanic communities in the U.S. with LC or cirrhosis [58,59]. Thus, Guatemala may encapsulate what appears to be a new and growing paradigm of LC etiology in both developed and developing nations. Finally, these findings could be used to inform appropriate cancer prevention strategies in Guatemala–aflatoxin exposure is a modifiable risk factor and effective, scalable, culturally competent, and economically feasible prevention strategies have been proposed and validated in low- and middle-income countries [14]. Further work to examine the associations between LC risk factors and incidence in this population is clearly needed.
Acknowledgments
The authors would like to thank the participants in this study. We also greatly appreciate the technical support from Dr. Carlos Mendoza-Montano, Dr. Manolo Mazariegos, Ms. Carol Resnick, and the administrative staff at INCAP and Johns Hopkins.
References
- 1. Wild CP, Bucher JR, De Jong BWD, Dillner J, Von Gertten C, Groopman JD, et al. Translational Cancer Research: Balancing Prevention and Treatment to Combat Cancer Globally. J Natl Cancer Inst. 2015;107. pmid:25515230
- 2.
International Agency for Research on Cancer WHO. World Cancer Report 2014. 2014. 9283204298
- 3. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol. Elsevier Ltd; 2012;13: 790–801. pmid:22658655
- 4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136: E359–E386. pmid:25220842
- 5. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015;65: 87–108. pmid:25651787
- 6. Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer. 2016;139: 1534–1545. pmid:27244487
- 7. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122: 1312–1337. pmid:26959385
- 8. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2016;2: 16018. pmid:27158749
- 9. Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, Park JH, et al. Dramatic reduction of liver cancer incidence in young adults: 28 Year follow-up of etiological interventions in an endemic area of China. Carcinogenesis. 2013;34: 1800–1805. pmid:23322152
- 10. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year follow-up study. J Natl Cancer Inst. 2009;101: 1348–1355. pmid:19759364
- 11. Chen J-G, Egner PA, Ng D, Jacobson LP, Muñoz A, Zhu Y-R, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res. 2013;6: 1038–45. pmid:23963804
- 12. Makarova-Rusher O V., Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122: 1757–1765. pmid:26998818
- 13. Kensler TW, Roebuck BD, Wogan GN, Groopman JD. Aflatoxin: A 50-year odyssey of mechanistic and translational toxicology. Toxicol Sci. 2011;120: S28–S48. pmid:20881231
- 14.
International Agency for Research on Cancer WHO. Mycotoxin control in low- and middle-income countries. Wild CP, Miller JD, Groopman JD, editors. 2015.
- 15.
International Agency for Research on Cancer WHO. Some naturally occurring substances: Food items and constituents, heterocyclic aromatic amines and mycotoxins. IARC Monographs on the Evaluation of Carcinogenic Risks To Humans. 1993. 10.1002/food.19940380335
- 16.
International Agency for Research on Cancer WHO. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monographs on the Evaluation of Carcinogenic Risks To Humans. 2002. 10.1002/food.19940380335
- 17. Liu Y, Wu F. Global burden of Aflatoxin-induced hepatocellular carcinoma: A risk assessment. Environ Health Perspect. 2010;118: 818–824. pmid:20172840
- 18. Liu Y, Chang C-CH, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer. Elsevier Ltd; 2012;48: 2125–36. pmid:22405700
- 19. de Campos M, Olszyna-Marzys AE. Aflatoxin contamination in grains and grain products during the dry season in Guatemala. Bull Environ Contam Toxicol. 1979;22: 350–356. pmid:465803
- 20. de Campos M, Santos JC, Olszyna-Marzys AE. Aflatoxin contamination in grains from the Pacific coast in Guatemala and the effect of storage upon contamination. Bull Environ Contam Toxicol. 1980;24: 789–795. pmid:7459468
- 21. Torres O, Matute J, Gelineau-van Waes J, Maddox JR, Gregory SG, Ashley-Koch AE, et al. Human health implications from co-exposure to aflatoxins and fumonisins in maize-based foods in Latin America: Guatemala as a case study. World Mycotoxin J. 2015;8: 143–159.
- 22. Ross RK, Yuan J-M, Yu MC, Wogan GN, Qian G-S, Tu J-T, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet. 1992;339: 943–946. pmid:1348796
- 23. Qian G-S, Ross RK, Yu MC, Yuan J-M, Gao Y-T, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol Biomarkers Prev. 1994;3: 3–10. pmid:8118382
- 24. Sabbioni G, Skipper PL, Büchi G, Tannenbaum SR. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis. 1987;8: 819–824. pmid:3111739
- 25. Sabbioni G, Ambs S, Wogan GN, Groopman JD. The aflatoxin-lysine adduct quantified by high-performance liquid chromatograplhy from human serum albumin samples. Carcinogenesis. 1990;11: 2063–2066. pmid:2121383
- 26. Wu H-C, Wang Q, Yang H-I, Ahsan H, Tsai W-Y, Wang L-Y, et al. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev. 2009;18: 846–53. pmid:19273485
- 27. Sabbioni G, Turesky RJ. Biomonitoring Human Albumin Adducts: The Past, the Present, and the Future. Chem Res Toxicol. 2017;30: 332–366. pmid:27989119
- 28. McGlynn KA, Petrick JL, London WT. Global Epidemiology of Hepatocellular Carcinoma: An Emphasis on Demographic and Regional Variability. Clin Liver Dis. Elsevier Inc; 2015;19: 223–238. pmid:25921660
- 29. McCoy LF, Scholl PF, Schleicher RL, Groopman JD, Powers CD, Pfeiffer CM. Analysis of aflatoxin B1-lysine adduct in serum using isotope-dilution liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19: 2203–2210. pmid:16015671
- 30. Heidrich B, Cetindere A, Beyaz M, Stahmeyer JT, Basaran MM, Braynis B, et al. High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting. Eur J Gastroenterol Hepatol. 2014;26: 1090–7. pmid:25076065
- 31. Soini Y, Chia SC, Bennett WP, Groopman JD, Wang JS, DeBenedetti VMG, et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis. 1996;17: 1007–1012. pmid:8640905
- 32. Carvajal M, Berumen J, Guardado-Estrada M. The presence of aflatoxin B(1)-FAPY adduct and human papilloma virus in cervical smears from cancer patients in Mexico. Food Addit Contam Part A. 2012;29: 258–268. pmid:22273520
- 33. Diaz GJ, Sánchez MP. Determination of aflatoxin M1 in breast milk as a biomarker of maternal and infant exposure in Colombia. Food Addit Contam Part A. Taylor & Francis; 2015;32: 1192–1198. pmid:25959253
- 34. Noguier L, Foerster C, Groopman JD, Egner PA, Koshiol J, Ferreccio C. Association of Aflatoxin With Gallbladder Cancer in Chile. J Am Med Assoc. 2015;313: 26–28. pmid:26010638
- 35. Jager A V., Tonin FG, Baptista GZ, Souto PCMC, Oliveira CAF. Assessment of aflatoxin exposure using serum and urinary biomarkers in São Paulo, Brazil: A pilot study. Int J Hyg Environ Health. Elsevier GmbH.; 2016;219: 294–300. pmid:26740158
- 36. De Carvalho FM, De Almeida Pereira T, Gonçalves PL, Jarske RD, Pereira FEL, Louro ID. Hepatocellular carcinoma and liver cirrhosis TP53 mutation analysis reflects a moderate dietary exposure to aflatoxins in Espírito Santo State, Brazil. Mol Biol Rep. 2013;40: 4883–4887. pmid:23649769
- 37. Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. J Clin Oncol. 2016;34: 1787–1794. pmid:27044939
- 38. Pinheiro PS, Callahan KE, Siegel RL, Jin H, Morris CR, Trapido EJ, et al. Cancer mortality in Hispanic ethnic groups. Cancer Epidemiol Biomarkers Prev. 2017;26: 376–382. pmid:28223429
- 39. Ramirez AG, Munoz E, Holden AEC, Adeigbe RT, Suarez L. Incidence of Hepatocellular Carcinoma in Texas Latinos, 1995–2010: An update. PLoS One. 2014;9: 1–5. pmid:24915432
- 40. Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin. 2017;0: 1–17. pmid:28586094
- 41. Rivera-Andrade A, Kroker-Lobos MF, Lazo M, Freedman ND, Groopman JD, Guallar E, et al. Comparison of Metabolic Risk Factors for Liver Cancer Among Men and Women in Guatemala. Journal of Global Oncology. 2017. p. 10s–11s.
- 42. Wild CP, Garner RC, Montesano R, Tursi F. Aflatoxin B1 binding to plasma albumin and liver DNA upon chronic administration to rats. Carcinogenesis. 1986;7: 853–858. pmid:3085966
- 43. Cupid BC, Lightfoot TJ, Russell D, Gant SJ, Turner PC, Dingley KH, et al. The formation of AFB1-macromolecular adducts in rats and humans at dietary levels of exposure. Food Chem Toxicol. 2004;42: 559–569. pmid:15019179
- 44. Jubert C, Mata J, Bench G, Dashwood R, Pereira C, Tracewell W, et al. Effects of chlorophyll and chlorophyllin on low-dose aflatoxin B 1 pharmacokinetics in human volunteers. Cancer Prev Res. 2009;2: 1015–1022. pmid:19952359
- 45. Skipper PL, Tannenbaum SR. Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis. 1990;11: 507–518. pmid:2182215
- 46. Groopman JD, Jiaqi Z, Donahue PR, Pikul A, Lisheng Z, Jun-shi C, et al. Molecular Dosimetry of Urinary Aflatoxin-DNA Adducts in People Living in Guangxi Autonomous Region, People’s Republic of China. Cancer Res. 1992;52: 45–52. pmid:1727385
- 47. Groopman JD, Hall AJ, Montesano R, Wild CP, Whittle H, Hudson GJ, et al. Molecular Dosimetry of Aflatoxin-N7-guanine In Human Urine Obtained in The Gambia, West Africa. Cancer Epidemiol Biomarkers Prev. 1992;1: 221–227. pmid:1339082
- 48. Sun C-A, Wu D-M, Wang L-Y, Chen C-J, You S-L, Santella RM. Determinants of formation of aflatoxin-albumin adducts: a seven-township study in Taiwan. Br J Cancer. 2002;87: 966–70. pmid:12434285
- 49. Gong Y, Egal S, Hounsa A, Turner PC, Hall AJ, Cardwell KF, et al. Determinants of aflatoxin exposure in young children from Benin and Togo, West Africa: The critical role of weaning. Int J Epidemiol. 2003;32: 556–562. pmid:12913029
- 50. Shirima CP, Kimanya ME, Kinabo JL, Routledge MN, Srey C, Wild CP, et al. Dietary exposure to aflatoxin and fumonisin among Tanzanian children as determined using biomarkers of exposure. Mol Nutr Food Res. 2013;57: 1874–1881. pmid:23776058
- 51. Groopman JD, Egner PA, Schulze KJ, Wu LS-F, Merrill R, Mehra S, et al. Aflatoxin exposure during the first 1000 days of life in rural South Asia assessed by aflatoxin B1-lysine albumin biomarkers. Food Chem Toxicol. 2014;74: 184–189. pmid:25308602
- 52. Bowden S. Serological and Molecular Diagnosis. Semin Liver Dis. 2006;26: 97–103. pmid:16673288
- 53. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004;24: 3–8. pmid:15346240
- 54. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet. 2015;386: 1546–1555. pmid:26231459
- 55. Alvarado-Mora M V., Rebello Pinho JR. Epidemiological update of hepatitis B, C and delta in Latin America. Antivir Ther. 2013;18: 429–433. pmid:23792375
- 56. Beasley RP, Hwang L-Y, Lin C-C, Chien C-S. Hepatocellular Carcinoma and Hepatitis B Virus: A Prospective Study of 22,707 Men in Taiwan. Lancet. 1981; 1129–1133. pmid:6118576
- 57. Ropero Álvarez AM, Pérez-Vilar S, Pacis-Tirso C, Contreras M, El Omeiri N, Ruiz-Matus C, et al. Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas. BMC Public Health. BMC Public Health; 2017;17: 325. pmid:28415981
- 58. Johnson NM, Qian G, Xu L, Tietze D, Marroquin-Cardona A, Robinson A, et al. Aflatoxin and PAH exposure biomarkers in a U.S. population with a high incidence of hepatocellular carcinoma. Sci Total Environ. 2010;408: 6027–6031. pmid:20870273
- 59. Jiao J, Watt GP, Lee M, Rahbar MH, Vatcheva KP, Pan JJ, et al. Cirrhosis and advanced fibrosis in Hispanics in Texas: The dominant contribution of central obesity. PLoS One. 2016;11: 1–14. pmid:26950933